Treatment

A real-world study evaluated tarlatamab (Imdelltra) in 23 patients with extensive-stage small cell lung cancer (ES-SCLC), a group with higher disease burden than typical clinical trials. Many patients were older (median age 72), 61% had brain metastases, and 43% had received two or more prior treatments. Among 18 evaluable patients, the objective response rate was […]

Results from a phase 1/1b study suggest that combining pembrolizumab (Keytruda) with ficerafusp alfa (BCA101) may improve outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), particularly those with HPV-negative disease. Ficerafusp alfa is a novel antibody designed to block both EGFR and TGF-β, two pathways linked to treatment resistance.

New analyses from the phase 3 EPCORE FL-1 trial showed that adding epcoritamab (Epkinly) to lenalidomide and rituximab provides significantly better outcomes than lenalidomide and rituximab alone for patients with relapsed or refractory follicular lymphoma. Earlier results showed the triplet reduced the risk of disease progression or death by 79%, with an overall response rate

A phase 1b/2 study found that adding the IDH1 inhibitor ivosidenib to the standard combination of venetoclax and azacitidine produced deep and durable responses in patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) who were not candidates for intensive chemotherapy. The trial enrolled 40 patients with a median age of 72 years. Patients received

A large real-world study found that zanubrutinib (Brukinsa) was associated with better outcomes than acalabrutinib (Calquence) in patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers analyzed insurance claims data from nearly 16,800 patients, including 5,819 treated with zanubrutinib and 10,969 treated with acalabrutinib. Patient characteristics were similar between the

Researchers tested an existing cancer drug, panitumumab (Vectibix), in a rare and aggressive kidney cancer called SMARCB1-deficient renal medullary carcinoma. Because the drug is already approved for other cancers, they were able to quickly run a multi-region study in North America and Europe. In 26 heavily pretreated patients, the results were stronger than expected. About

During a virtual Case-Based Roundtable, Daniel Landau and community oncologists discussed frontline treatment options for a 65-year-old man with newly diagnosed poor-risk metastatic clear cell renal cell carcinoma (ccRCC) and extensive bone involvement. The panel agreed that the immediate priority in such patients is rapid tumor reduction to prevent complications such as spinal cord compression

A large real-world analysis suggests that zanubrutinib (Brukinsa) may provide better outcomes than acalabrutinib (Calquence) and ibrutinib (Imbruvica) when used as first-line treatment for older patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers analyzed Medicare data from 10,523 patients aged 65 years and older who began treatment between January 2020 and

Researchers have reported promising results from a Phase II clinical trial evaluating sacituzumab govitecan in patients with advanced uterine cancer. The study enrolled 50 women whose disease had continued to progress despite standard treatments. Results showed that 70% of participants experienced tumor shrinkage, and 28% achieved a substantial reduction of at least 30%. These outcomes

The Phase 3 EMERALD-3 trial found that adding immunotherapy to standard treatment significantly delayed disease progression in patients with unresectable hepatocellular carcinoma (HCC) eligible for transarterial chemoembolization (TACE). The study enrolled 760 patients and compared STRIDE immunotherapy (tremelimumab plus durvalumab) combined with lenvatinib and TACE, STRIDE plus TACE, and TACE alone. Patients receiving the full combination